Join today and have your say! It’s FREE!
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alpha Cognition Inc ACOG

Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062... see more

Recent & Breaking News (NDAQ:ACOG)

Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer's Disease, in China

Business Wire 4 days ago

Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer's Long-Term Care Market During Investor Update Call

Business Wire 6 days ago

Alpha Cognition Announces Partial Exercise of Over-allotment Option

Business Wire December 16, 2024

CSE Bulletin: Delist - Alpha Cognition Inc. (ACOG)

Newsfile December 16, 2024

Alpha Cognition Announces Voluntary Delisting from CSE

Business Wire December 12, 2024

Alpha Cognition sees promising data for military-related trauma treatment

Jonathon Brown December 11, 2024

Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury

Business Wire December 11, 2024

Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update

Business Wire November 15, 2024

Canadian Investment Regulatory Organization Trade Resumption - ACOG

Canada NewsWire November 12, 2024

Alpha Cognition Announces Pricing of $50 Million Upsized Public Offering and Nasdaq Listing

Business Wire November 12, 2024

Canadian Investment Regulatory Organization Trading Halt - ACOG

Canada NewsWire November 12, 2024

Alpha Cognition Announces Proposed Financing and Share Consolidation in connection with Nasdaq Uplisting

Business Wire October 31, 2024

Alpha Cognition Announces Appointment of VP Finance and Accounting

Business Wire October 21, 2024

Alpha Cognition Receives Notice of Allowance for Composition-of-Matter Patent for ZUNVEYLTM for Mild to Moderate Alzheimer's Disease

Business Wire October 15, 2024

Alpha Cognition Announces Change of Officer

Business Wire October 3, 2024

Alpha Cognition Announces Completion of $4.545 Million (USD) Convertible Note and Warrants Bridge Financing

Business Wire September 24, 2024

Alpha Cognition Receives Notice of Allowance for Composition-of-Matter Patent for ZUNVEYL® for Mild to Moderate Alzheimer's Disease

Business Wire August 19, 2024

Alpha Cognition, Inc. On Track to Secure Financing for Continued Growth

Business Wire August 13, 2024

Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update

Business Wire August 12, 2024

FDA approves Alpha Cognition's Zunveyl to treat Alzheimer's disease

Trevor Abes  July 29, 2024